Floatz logo

Berzosertib

Ovarian Endometrioid Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Ovarian Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
DOXORUBICIN
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2BB

View all 50 →

Same molecule, other indications

Berzosertib is also rated in:

small cell lung carcinomaActive
BBB
Indicative · Phase 2
73 / 100
View asset →
small cell carcinomaActive
BB
Indicative · Phase 2
64 / 100
View asset →
fallopian tube carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →